Shifting Medicine Forward
Drawing on a deep understanding of the underlying causes of some of the most challenging diseases, Ichnos Sciences is pursuing truly disease-centric therapies in oncology and autoimmune disease. We strive to develop novel assets and find new answers to some of medicine’s greatest challenges. Because the world is waiting.
Our path toward disease-centric therapies
oncology
| Compound | Mechanism | Preclinical | IND-Enabling | phase 1 | phase 2 | phase 3 |
|---|---|---|---|---|---|---|
| ISB 1302 | HER2 x CD3 BEAT® bispecific antibody |
|||||
| ISB 1342 | CD38 x CD3 BEAT® bispecific antibody |
|||||
| ISB 1908 | T-cell engager | 2H 2020 | ||||
| ISB 1909 | T-cell engager | 1H 2021 | ||||
| ISB 1442 | Innate immune engager | 2H 2020 | ||||
| ISC XXXXX | HPK1 inhibitor | 2H 2020 |
oncology
-
Metastatic HER2 + Breast CancerISB 1302HER2 x CD3 BEAT®
bispecific antibody -
-
Relapsed/Refractory Multiple Myeloma (MM)ISB 1342CD38 x CD3 BEAT®
bispecific antibody -
-
ISB 1908T-cell engager
-
2H 2020
-
ISB 1909T-cell engager
-
1H 2021
-
ISB 1442Innate immune engager
-
2H 2020
-
ISC XXXXXHPK1 inhibitor
-
2H 2020
autoimmune disease
| Compound | Mechanism | Preclinical | IND-Enabling | phase 1 | phase 2 | phase 3 |
|---|---|---|---|---|---|---|
| ISB 830 | OX40 antagonist monoclonal antibody | |||||
| ISB 880 | Targeted anti-inflammatory therapy | 2H 2020 |
autoimmune disease
-
Atopic Dermatitis (AD)ISB 830OX40 antagonist monoclonal antibody
-
-
ISB 880Targeted anti-inflammatory therapy
-
2H 2020
pain management
| Compound | Mechanism | Preclinical | IND-Enabling | phase 1 | phase 2 | phase 3 |
|---|---|---|---|---|---|---|
| ISC 17536* | TRPA1 antagonist |
pain management
-
Diabetic Peripheral Neuropathy (DPN)ISC 17536*TRPA1 antagonist
-
*Ichnos Sciences will complete preclinical and clinical work required to start a randomized Phase 2b study of ISC 17536 and plans to out-license the compound to enable greater focus on oncology and autoimmune disease.
Note: Assets that were previously identified as GBR and GRC are now identified as ISB (for biologics) and ISC (for small molecules), respectively.
View Career Opportunities
The links above are provided for your convenience, and Ichnos is not responsible for content, privacy or security issues associated with your visit to external websites.
